Rossari Biotech Limited has officially announced an earnings conference call to discuss its Q3 FY26 financial performance with investors and analysts. The company filed this intimation with stock exchanges under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Call Details

The earnings conference call has been scheduled with specific parameters for participant access:

Meeting Structure and Agenda

The conference call will follow a structured format designed to provide comprehensive insights into the company's quarterly performance. The session will commence with a brief management discussion covering financial results for the quarter and nine months ended December 31, 2025. Following the management presentation, an interactive Question & Answer session will allow participants to engage directly with the senior management team.

Pre-Registration and Access

To enhance participant experience, Rossari Biotech has arranged for zero wait time access through pre-registration. Participants can register in advance using the provided DiamondPass system, eliminating the need to wait for operator assistance when joining the call.

Company Background

Rossari Biotech Limited operates as a specialty chemicals manufacturer, providing intelligent and sustainable solutions across multiple industries. The Mumbai-headquartered company maintains strategically located manufacturing facilities at Silvassa and Dahej. The company's product portfolio spans Home, Personal Care and Performance chemicals (HPPC), Textile specialty chemicals, and Animal Health and Nutrition (AHN) segments.

Regulatory Compliance

The earnings call announcement was signed by Parul Gupta, Head - Company Secretary & Legal (Membership No.: A38895), and submitted to both BSE Limited and National Stock Exchange of India Limited on January 13, 2026. This filing ensures compliance with mandatory disclosure requirements for listed companies regarding investor communication activities.

Rossari Biotech has announced the incorporation of a new subsidiary named Rossari (Singapore) Pte. Ltd. This strategic corporate development marks the company's expansion into the Singapore market through the establishment of an international subsidiary.

Corporate Structure Development

The creation of Rossari (Singapore) Pte. Ltd. represents a significant step in Rossari Biotech's organizational growth and international presence. This subsidiary structure will enable the company to establish operations in Singapore and potentially serve as a hub for broader regional activities.

Strategic Implications

The establishment of this Singapore-based subsidiary demonstrates Rossari Biotech's commitment to expanding its geographical footprint beyond domestic markets. Singapore's strategic location and business-friendly environment make it an attractive destination for companies looking to establish regional operations.

This corporate development reflects the company's growth strategy and its focus on building an international presence through structured subsidiary operations. The new entity will operate under the Rossari brand while maintaining its connection to the parent company's core business activities.

By incorporating Rossari (Singapore) Pte. Ltd., Rossari Biotech aims to strengthen its international presence and potentially explore new business opportunities in the Southeast Asian market. This move aligns with the company's broader strategy of expanding its global reach and enhancing its competitive position in the international marketplace.